Early and midterm results of the patients with PDA and VSD closed using Amplatzer duct occluder

  • Nazan Ozbarlas, Department of Pediatric Cardiology, Faculty of Medicine, Cukurova University, Adana Turkey, Turkey
  • Dr Osman Kucukosmanoglu, Department of Pediatric Cardiology, Faculty of Medicine, Cukurova University, Adana Turkey, Turkey
  • Sevcan Erdem, Department of Pediatric Cardiology, Faculty of Medicine, Cukurova University, Adana Turkey, Turkey
  • Alev Kiziltas, Department of Pediatric Cardiology, Faculty of Medicine, Cukurova University, Adana Turkey, Turkey
  • Abdi Bozkurt, Department of Cardiology, Faculty of Medicine, Cukurova University, Adana Turkey, Turkey

    • In this report we review initial and 4-year results following transcatheter occlusion of patent ductus artriozus (PDA) and ventricular septal defect (VSD) using Amplatzer duct occluder (ADO) and ADO II.
    Between November 2004 and 2008, 66 patients, ages ranged 7 months to 66 years, underwent transcatheter closure using the ADO and ADO II. Two muscular VSDs were closed with ADO.
    The mean pulmonary artery pressure was 25,8 mmHg (median 24 mmHg, 12 to 60 mmHg) and 24 of them were greater then 25 mmHg. The mean PDA diameter (at the pulmonary end) was 3,3 mm (range 1,6 to 7,5 mm), the PDA length was 7,0 mm (range 3 to 16 mm) and the mean ampulla diameter (at the aortic end) was 10,5 mm (range 5,3 to 23 mm). For closure of PDA, 52 ADO and 14 ADO II were used. Two patient’s muscular VSD were closed with ADO. Occlusion of femoral artery was developed only one patient and there was not another complication in early period. Complete closure was observed in 67/68 (98,5%) patients. None of the patients developed increased velocity across the left pulmonary artery and descending aorta. The mean follow up period was 7,9 months (median 2,5 months, 1 to 42 months). No early or late evidence of device failure, recanalization, endocarditis, thromboembolism, or hemolysis were observed.
    Our results provide that transcatheter closure using ADO can safely and effectively in treatment of PDA and it can be use for closure of some of muscular VSD.